Rociverine for nocturia in the elderly.

Forty inpatient men and women, between 50 and 80 years of age, with nocturia due to bladder instability, resorption of postural edema, or senile involution were admitted to a clinical trial designed to test the possibility of reducing or eliminating nocturnal voidings by means of a single evening dose of rociverine or flavoxate. This six-day crossover trial was divided into three periods of two days each: pretrial, treatment with one drug, and treatment with the other drug. Either 20 mg of rociverine or 200 mg of flavoxate was given at 8 PM in randomized sequence. For each night of the study, the following data were recorded: interval between drug administration and first voiding, volume of first voiding, total volume of nocturnal urine, total volume of nocturnal urine plus volume of urine passed on waking, and total number of nocturnal voidings. The outcome was a significant reduction of the number of nocturnal voidings together with a marked lengthening of the interval between drug administration and first voiding, with no noteworthy differences between the two drugs. Considering the efficacy of rociverine and, even more important, the excellent tolerance of elderly patients to the drug, further study of rociverine in nocturia and in urinary incontinence seems indicated.

Rociverine for nocturia in the elderly: medium-term controlled clinical trial.

Forty patients, aged 51 to 79 years, with nocturia due to bladder instability, resorption of postural edema, or senile decay, were treated with rociverine or flavoxate to test the possibility of reducing or eliminating nocturnal voidings. After a two-day observation period, each patient received either 20 mg of rociverine or 200 mg of flavoxate in a single dose at 8 PM. The following were assessed before the trial and after 14 and 28 days of treatment: number of night voidings, interval between drug administration and first voiding, volume of first voiding, volume of urine voided during the night, volume of morning urine, and total volume of urine passed between 8 PM and 8 AM. Routine laboratory tests performed before and after the trial showed both drugs to be well tolerated. The results of the trial show that rociverine reduced the number of night voidings significantly more (P less than 0.05) than did flavoxate.

Sulphinpyrazone in cardiovascular elderly azotemic patients: a proposal of a 'guided' incremental dose schedule.

Renal tolerability of a guided incremental dose schedule of sulphinpyrazone was evaluated in an open study of 2-month duration, performed in twenty-one cardiovascular elderly azotemic patients (thirteen males, eight females; mean age: 79 years, S.D.: 7 X 3 years). Starting dosage was 200 mg per day; daily dosage was then increased, every 4 days, by 200 mg or kept constant for another 4 days, according to each patient's basal renal function, up to the maintenance dose: 800 mg/day. Eighty-one per cent of the patients followed a successful incremental pathway, 9% kept a constant daily dosage of 200 mg for 8 days, reaching then the maintenance daily dose without any problems. Nine per cent withdrew at 200 mg/day because renal function deteriorated at two consecutive visits. Renal function of the patients who completed the study significantly improved (two-way ANOVA, p less than 0.01). General tolerability was good. The proposed incremental dose schedule of sulphinpyrazone can be successfully used in the treatment of cardiovascular elderly azotemic patients.